Stopping Pentosan Polysulfate After Twelve Years: An Early Retinal Finding Against Modest Relief
Twelve years of a drug that never worked especially well, now flagged for a retinal risk that may already be doing its damage regardless of what happens today.
The referral came from ophthalmology, which is not where a bladder problem usually begins. Sylvia R., 61, was diagnosed with interstitial cystitis/bladder pain syndrome fourteen years ago after a long diagnostic process involving multiple prior misdiagnoses, and has taken pentosan polysulfate for the past twelve of those years — one of several therapies tried, and the only one that brought her pelvic pain and urinary frequency down to a level she calls "livable," even though she has never described the relief as complete. She has no diabetes, no other chronic conditions, and no history of retinal disease of any kind before this visit.
A routine dilated eye exam three weeks ago — part of the ophthalmologic screening now recommended for patients with extended pentosan polysulfate exposure — found early pigmentary changes in both maculae, findings her ophthalmologist read as consistent with, though not yet advanced examples of, the maculopathy first described by Pearce and colleagues in a 2018 case series and formally recognized in a 2020 FDA label update warning of retinal pigmentary changes with chronic use. Her visual acuity remains normal today, and she has noticed no symptoms herself — the finding was entirely incidental to the screening, which matters because she paints watercolor landscapes and has taught a weekend workshop out of her home studio for close to twenty years, so the acuity that currently reads as normal is also the faculty she would notice losing first. What makes her case genuinely difficult, not just alarming, is that pentosan polysulfate's own efficacy for interstitial cystitis was modest even in the trials that led to its original approval. The one thing no one can tell her is the thing she most needs: whether the twelve years already behind her, rather than any year still ahead, are what will decide how her retina looks in a decade.
Twelve years of modest relief against an early retinal finding
I'd stop the pentosan polysulfate today. Pearce's 2018 case series first characterized this exact pigmentary pattern in long-term users, and the FDA's 2020 label update formally recognized it as a real, dose- and duration-dependent risk. Her exam already shows early changes consistent with that pattern. And it's worth saying plainly — this drug's own approval was never based on strong efficacy data. We're not trading away a highly effective therapy.
I don't dispute the ocular finding, but I want to be honest about what stopping actually costs her. It took years to get her pelvic pain to a level she calls livable, and interstitial cystitis has a genuinely thin bench of alternatives — nothing else has reliably matched what pentosan has done for her specifically. There's also a harder question underneath this: Huckfeldt and Vavvas documented maculopathy that continued to progress after pentosan polysulfate was discontinued, which means her current findings may already represent damage that stopping today doesn't reverse.
If that's true, we may be giving up real symptom control without necessarily protecting the vision that's already been affected.
I take that uncertainty seriously, but I don't think it argues for continuing. The published case series consistently show worse maculopathy with longer cumulative duration and higher cumulative dose — whatever damage exists today, more exposure is the one variable we can still control. We can't undo twelve years, but stopping now is the only lever actually available to limit whatever comes next.
Nobody can tell her in advance whether her findings will progress either way — but that uncertainty cuts toward removing the exposure, not toward continuing it on the chance it won't.
Agreed: discontinue pentosan polysulfate and begin amitriptyline, with ophthalmologic follow-up in three months to assess whether her retinal findings remain stable or progress despite discontinuation.
Not agreed: the pain medicine specialist remains genuinely unconvinced that stopping will meaningfully change her ocular outcome given Huckfeldt and Vavvas's documented post-discontinuation progression, and considers the decision a reasonable but not obviously correct trade of certain symptom loss against uncertain visual benefit; the ophthalmologist and urologist both consider the decision correct regardless of whether her maculopathy ultimately progresses, on the reasoning that removing an ongoing modifiable exposure is justified once real toxicity is documented, independent of how the individual case resolves.